Sanz-González SM - Search Results

1

Classic and novel roles of p53: prospects for anticancer therapy.

Fuster JJ, Sanz-González SM, Moll UM, Andrés V. Fuster JJ, et al. Trends Mol Med. 2007 May;13(5):192-9. doi: 10.1016/j.molmed.2007.03.002. Epub 2007 Mar 23. Trends Mol Med. 2007. PMID: 17383232 Review.

2

A mechanism of AP-1 suppression through interaction of c-Fos with lamin A/C.

Ivorra C, Kubicek M, González JM, Sanz-González SM, Alvarez-Barrientos A, O'Connor JE, Burke B, Andrés V. Ivorra C, et al. Genes Dev. 2006 Feb 1;20(3):307-20. doi: 10.1101/gad.349506. Genes Dev. 2006. PMID: 16452503 Free PMC article.

3

Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis.

Sanz-González SM, Barquín L, García-Cao I, Roque M, González JM, Fuster JJ, Castells MT, Flores JM, Serrano M, Andrés V. Sanz-González SM, et al. Cardiovasc Res. 2007 Sep 1;75(4):803-12. doi: 10.1016/j.cardiores.2007.05.002. Epub 2007 May 10. Cardiovasc Res. 2007. PMID: 17570351 Free article.

4

Role of E2F and ERK1/2 in STI571-mediated smooth muscle cell growth arrest and cyclin A transcriptional repression.

Sanz-González SM, Castro C, Pérez P, Andrés V. Sanz-González SM, et al. Biochem Biophys Res Commun. 2004 May 14;317(4):972-9. doi: 10.1016/j.bbrc.2004.03.143. Biochem Biophys Res Commun. 2004. PMID: 15094364 Free article.

5

Drug targeting of estrogen receptor signaling in the cardiovascular system: preclinical and clinical studies.

Sanz-González SM, Cano A, Valverde MA, Hermenegildo C, Andrés V. Sanz-González SM, et al. Curr Med Chem Cardiovasc Hematol Agents. 2004 Apr;2(2):107-22. doi: 10.2174/1568016043477251. Curr Med Chem Cardiovasc Hematol Agents. 2004. PMID: 15320794 Free article. Review.

6

Atheroma development in apolipoprotein E-null mice is not regulated by phosphorylation of p27(Kip1) on threonine 187.

Sanz-González SM, Melero-Fernández de Mera R, Malek NP, Andrés V. Sanz-González SM, et al. J Cell Biochem. 2006 Mar 1;97(4):735-43. doi: 10.1002/jcb.20680. J Cell Biochem. 2006. PMID: 16229012 Free article.

7

Inhibition of cellular proliferation by drug targeting of cyclin-dependent kinases.

Pérez-Roger I, Ivorra C, Díez A, Cortés MJ, Poch E, Sanz-González SM, Andrés V. Pérez-Roger I, et al. Curr Pharm Biotechnol. 2000 Jul;1(1):107-16. doi: 10.2174/1389201010001010107. Curr Pharm Biotechnol. 2000. PMID: 11467357 Free article. Review.

8

Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease.

Ivorra C, Samyn H, Edo MD, Castro C, Sanz-González SM, Déez-Juan A, Andrés V. Ivorra C, et al. Curr Pharm Biotechnol. 2003 Feb;4(1):21-37. doi: 10.2174/1389201033377977. Curr Pharm Biotechnol. 2003. PMID: 12570680 Free article. Review.

9

Control of vascular smooth muscle cell growth by cyclin-dependent kinase inhibitory proteins and its implication in cardiovascular disease.

Sanz-González SM, Poch E, Pérez-Roger I, Díez-Juan A, Ivorra C, Andrés V. Sanz-González SM, et al. Front Biosci. 2000 Jul 1;5:D619-28. doi: 10.2741/sanz. Front Biosci. 2000. PMID: 10877996 Free article. Review.

10

Atherosclerosis development in apolipoprotein E-null mice deficient for CD69.

Gómez M, Sanz-González SM, Abu Nabah YN, Lamana A, Sánchez-Madrid F, Andrés V. Gómez M, et al. Cardiovasc Res. 2009 Jan 1;81(1):197-205. doi: 10.1093/cvr/cvn227. Epub 2008 Aug 14. Cardiovasc Res. 2009. PMID: 18703531 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters